This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Miller M et al. for the PROVE IT-TIMI 22 Investigators (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51: 724–730
Schwartz GG et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718
Cannon CP et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504
Smith SC Jr et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47: 2130–2139
Grønholdt M et al. (1998) Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation 97: 34–40
Fruchart JC et al. (1999) Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10: 245–257
Rosenson RS (2003) Lipid-lowering drugs and rheology. In Lipids and Atherosclerosis Annual 2003. 19–35 (Eds Gaw A and Shepherd J) London: Martin Dunitz
Cromwell WC and Otvos JD (2006) Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 98: 1599–1602
Brunzell JD et al. (2008) Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512–1524
Otvos JD et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veteran Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556–1563
Otvos JD et al. (2002) Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-1 trial. Atherosclerosis 160: 41–48
Bakker-Arkema RG et al. (1996) Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128–133
Hunninghake DB (2001) Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines. Am J Cardiol 88 (Suppl): 37K–41K
Rosenson RS et al. (2007) Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30: 1945–1951
Rosenson RS (2007) Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am J Cardiol 99 (Suppl): 96B–104B
Crisby M et al. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103: 926–933
Rosenson RS 2008 Fenofibrate treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 6: 1319–1330
Rosenson RS et al. (2008) Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis 198: 381–388
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RS Rosenson has received speakers' bureau honoraria and research support and has acted as a consultant for Abbott and AstraZeneca. Dr Rosenson has also received speakers' bureau honoraria from Solvay. B Pitt declared no competing interests.
Rights and permissions
About this article
Cite this article
Rosenson, R., Pitt, B. Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nat Rev Cardiol 6, 98–100 (2009). https://doi.org/10.1038/ncpcardio1435
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1435
This article is cited by
-
Rationale and strategies for formulation development of oral fixed dose combination drug products
Journal of Pharmaceutical Investigation (2016)